ProStocks Logo
Unlimited Trades ₹899 Monthly
www.ProStocks.com
Contact us

Piramal Pharma Limited Rights Issue (Piramal Pharma Rights Issue 2023) Detail

₹1,050.00 Crores | Listing at BSE, NSE | Tue, Aug 8, 2023 - Thu, Aug 17, 2023

Rights Issue Detail
Messages
Subscription
Review
Allotment
BOA
News
Calc
FAQs
Piramal Pharma Limited Logo

Piramal Pharma Limited Rights Issue comprises 12.96 Cr equity shares aggregating to ₹1,050.00 Cr, offered at an issue price of ₹81 per share with a face value of ₹10 per share.

The record date for determining eligible shareholders is Aug 2, 2023, with the Rights Issue being offered in the entitlement ratio of 5:46.

As per the terms of payment, ₹81 per share payable in full at the time of application.

The Rights Issue opens on Aug 8, 2023 and closes on Aug 17, 2023.

The deemed date of allotment is Aug 23, 2023, following which the equity shares are expected to be credited to demat accounts on Aug 24, 2023 and listed on NSE and BSE on Aug 28, 2023.

ICICI Securities Ltd. is the Lead Manager to the issue and MUFG Intime India Pvt.Ltd. is the Registrar to the Issue.

Investors are advised to refer to the Piramal Pharma Limited Letter of Offer for detailed information, including risk factors, issue terms, and procedural details.

Record Date

Wed, Aug 2, 2023

Entitlement Ratio

5 : 46

Open Date

Tue, Aug 8, 2023

Close Date

Thu, Aug 17, 2023

Rights Issue Details

Rights Issue Timetable

Piramal Pharma Rights Issue 2023 Financial Information (Restated Consolidated)
Period Ended31 Mar 202131 Mar 202231 Mar 2023
Assets10,899.7812,797.0414,522.56
Revenue6,479.016,834.907,306.66
Profit After Tax835.03375.96-186.46
Net Worth5,076.756,069.945,968.45
Reserves and Surplus4,488.625,290.695,181.79
Total Borrowing2,910.194,023.285,504.77
Amount in ₹ Crore

About Piramal Pharma Limited

Incorporated in 2020, Piramal Pharma Limited a flagship company of Piramal Group offers pharmaceutical products and services across a domestic and global distribution network.

The company has 15 global manufacturing facilities and a global distribution network in over 100 countries.

Piramal Pharma includes:

  1. Piramal Pharma Solutions (PPS), is an integrated Contract Development and Manufacturing Organization (CDMO). It develops and manufactures solutions through a globally integrated network of facilities across the drug life cycle to innovators and generic companies.
  2. Piramal Critical Care (PCC), is a Complex Hospital Generics business whose product portfolio includes inhalation anesthetics, intrathecal therapies for spasticity and pain management, injectable pain and anesthetics, injectable anti-infectives, and other therapies.
  3. India Consumer Healthcare (ICH) business, selling over-the-counter products.

Objects of the Issue:

The company intends to utilize the net proceeds from the issue towards the funding of the following objects:

  1. Repayment or prepayment, in full or in part, of certain borrowings, and
  2. General corporate purposes.

Rights Issue Review

[Dilip Davda] The company has been posting increasing losses for the last three fiscals as well as for Q1 of FY24. That raises concern. Though the RI price is at a discount of 21.66% based on its last traded price of Rs. 103.40, well-informed/cash surplus investors may consider parking funds for long-term rewards. Promoter’s holding too is below 35% hinting alert. Read detail review...

Company Contact Information

Piramal Pharma Limited
Ground Floor, Piramal Ananta,
Agastya Corporate Park, Kamani Junction,
LBS Marg, Kurla, Mumbai 400 070
Mumbai, Maharashtra, 400070

Rights Issue Registrar

MUFG Intime India Pvt.Ltd.

Rights Issue Lead Manager(s)

  1. ICICI Securities Ltd.

Quick/Useful Links

Open an Instant Account with Zerodha

Rights Issue FAQs

The Piramal Pharma Rights Issue 2023 opens on Tue, Aug 8, 2023, and closes on Thu, Aug 17, 2023.

Piramal Pharma Rights Issue 2023 Schedule

Last Date for credit of Rights Entitlements
Last Date for renunciation of Rights EntitlementsThu, Aug 10, 2023
Issue Opening DateTue, Aug 8, 2023
Issue Closing DateThu, Aug 17, 2023
Date of Allotment (on or about)Wed, Aug 23, 2023
Date of Credit (on or about)Thu, Aug 24, 2023
Date of Listing (on or about)Mon, Aug 28, 2023
Piramal Pharma Rights Issue 2023 price is set at ₹81 per share.
The eligible shareholders are being offered 5 Rights Equity Share(s) for every 46 fully paid-up Equity Shares held on Record Date (Wed, Aug 2, 2023).
The record date for the Piramal Pharma Rights Issue 2023 is Wed, Aug 2, 2023.
The issue size of Piramal Pharma Rights Issue 2023 is of 12,96,29,630 equity shares at ₹81 per share aggregating up to ₹1,050.00 Crores.
The Letter of Offer for Piramal Pharma Rights Issue 2023 can be downloaded here.

You can apply for Piramal Pharma Rights Issue 2023 in two ways:

  1. Net Banking (ASBA)
  2. Registrar's Website (R-WAP Facility)

Steps to apply for Piramal Pharma Rights Issue 2023 using Net Banking (ASBA)

  1. Log in to the net banking account of your bank.
  2. Go to the 'IPO & Rights Issue' section.
  3. Check if the Piramal Pharma Rights Issue 2023 is available on the list.
  4. Click the Apply button next to the Piramal Pharma Rights Issue 2023.
  5. Fill and check your information.
  6. Submit the application.

Steps to apply for Piramal Pharma Rights Issue 2023 using Registrar's website (R-WAP)

  1. Visit registrar's website
  2. Go to the 'Rights Issue' section
  3. Select Piramal Pharma Rights Issue 2023 from the dropdown.
  4. Enter Demat Account Number.
  5. Fill the online application form.
  6. Validate and submit the application.
🔗 Piramal Pharma Rights Issue 2023 Latest Update
Read More About Rights Issue Shares

Compare: